Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    mk-0653c
Show Display Options
Rank Status Study
1 Active, not recruiting A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Conditions: Hypercholesterolemia;   Heterozygous Familial Hypercholesterolemia
Interventions: Drug: EZ 10 mg/Atorva 20 mg FDC;   Drug: EZ 10 mg/Atorva 10 mg FDC
2 Completed A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
Condition: Hypercholesterolemia
Interventions: Drug: Ezetimibe 10 mg;   Drug: Atorvastatin 10 mg;   Drug: Placebo for Ezetimibe 10 mg tablet;   Drug: Placebo for Atorvastatin 10 mg capsule;   Behavioral: Diet control/Daily Exercise
3 Completed
Has Results
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
Condition: Hypercholesterolemia
Interventions: Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Ezetimibe/atorvastatin;   Drug: Placebo to atorvastatin;   Drug: Placebo to ezetimibe;   Drug: Placebo to ezetimibe/atorvastatin
4 Completed
Has Results
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
Condition: Hypercholesterolemia
Interventions: Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Ezetimibe/atorvastatin;   Drug: Placebo to atorvastatin;   Drug: Placebo to ezetimibe;   Drug: Placebo to ezetimibe/atorvastatin
5 Completed
Has Results
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe 10 mg;   Drug: atorvastatin;   Drug: Comparator: rosuvastatin

Study has passed its completion date and status has not been verified in more than two years.